Antibodies

Latest articles from this sub-category

News releases from this sub-category

Showing 101-125 of 196 articles

first
1
2
3
4
5
6
7
next

Progress in avian transgenics biomanufacturing

Oxford BioMedica, a gene therapy company, has announced progress in the programme of its collaborative partner Viragen

News from Oxford BioMedica, Jul 24, 2006

Grant for Monudin from motor neurone association

The UK Motor Neurone Disease (MND) Association has awarded Oxford BioMedica a grant to support preclinical evaluation of Monudin for the treatment of Amyotrophic Lateral Sclerosis (ALS)

News from Oxford BioMedica, Jul 20, 2006

Key lentivector patents in China

Oxford BioMedicareports that the Patent Office of the Peoples' Republic of China has granted two patents to the company that have broad claims covering vectors derived from lentiviruses

News from Oxford BioMedica, Jul 20, 2006

Lentivector licensing agreement with Pfizer

Oxford BioMedica, a gene therapy company, has signed a licence agreement for its LentiVector technology with Pfizer

News from Oxford BioMedica, Jul 20, 2006

Report of avian transgenic milestone

Oxford BioMedica, Viragen, and the Roslin Institute (Scotland) today announced a breakthrough in their collaborative project to develop avian transgenic biomanufacturing

News from Oxford BioMedica, Jul 20, 2006

European patent for Trovax covering 5T4 tumour

He European Patent Office has granted a key patent (No EP1036091), that provides broad protection for Oxford BioMedica's lead product, TroVax

News from Oxford BioMedica, Jul 20, 2006

More kinase assay kits for drug discovery

Serologicals says that Upstate Group, its wholly owned subsidiary, has expanded its Kinease FP product line to include each of the 80 individual kinases that have been validated in the assay

News from Chemicon International, Jul 19, 2006

More cost efficient Western blotting detection

Serologicals announced that Upstate, its subsidiary, has released a new, more cost efficient Western blotting detection kit based on its high quality Visualizer western blot detection kit

News from Chemicon International, Jul 19, 2006

Commercialising human stem cell technology

Chemicon International Enters into a license to commercialise research products utilising human embryonic stem cell technology from Wisconsin Alumni Research Foundation (Warf)

News from Chemicon International, Jul 19, 2006

Antibody therapy for treatment of solid tumours

Oxford Biomedica announces presentation by Wyeth Pharmaceuticals of preclinical efficacy data with antibody-targeted therapy for cancer

News from Oxford BioMedica, Jul 18, 2006

Phase II results with Metxia in pancreatic cancer

Oxford BioMedica announced that a clinician at the Royal Liverpool University Hospital, UK, presented further data from the first stage of the Phase II trial of MetXia in pancreatic cancer

News from Oxford BioMedica, Jul 18, 2006

Encouraging Phase II results in renal carcinoma

The data show that TroVax is safe and well tolerated in this patient group and that the product induces a strong anti-tumour immune response against the 5T4 tumour antigen

News from Oxford BioMedica, Jul 18, 2006

Successful Phase II trial in pancreatic cancer

Oxford BioMedica announced that the first stage of its Phase II trial in pancreatic cancer with MetXia, the company's gene targeted prodrug activation product, has been successfully completed

News from Oxford BioMedica, Jul 18, 2006

Patent allowance extends Trovax protection in USA

Oxford BioMedica reports that the US Patent and Trademark Office has issued a Notice of Allowance for a key patent application, which extends the protection of TroVax, its lead cancer vaccine

News from Oxford BioMedica, Jul 14, 2006

Phase II trial with Trovax in renal cell carcinoma

Oxford BioMedica reports that the first patient has been treated in a second Phase II trial with TroVax in combination with interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (RCC)

News from Oxford BioMedica, Jul 14, 2006

Innurex nerve regeneration programme highlighted

Oxford BioMedica repots that its Innurex programme for treating spinal cord injury was highlighted in a briefing at the Science Media Centre in London for the Applied Genomics Link programme

News from Oxford BioMedica, Jul 14, 2006

Lentivector licensing agreement signed

Oxford BioMedica has signed its seventh licence agreement for its LentiVector technology with a Fortune 500 global biopharmaceutical company

News from Oxford BioMedica, Jul 14, 2006

License to use RheoSwitch

Chemicon and RheoGene sign license to use RheoSwitch and related technologies within Chemicon's research product lines focused on specialty research markets, including stem cell biology portfolio